Clinical trials
Multiple Myeloma trials in the United States with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
50 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2002 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 4 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 50 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Oncotherapeutics | 4 |
| Herbert Irving Comprehensive Cancer Center | 3 |
| Cylene Pharmaceuticals | 2 |
| Medical College of Wisconsin | 2 |
| Sorrento Therapeutics, Inc. | 2 |
| American Society of Hematology | 1 |
| Ascentage Pharma Group Inc. | 1 |
| Benovus Bio, Inc. | 1 |
| Celularity Incorporated | 1 |
| Celyad Oncology SA | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 50 |
| Neoplasms, Plasma Cell | 19 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 9 |
| Lymphoma | 9 |
| Lymphoma, Non-Hodgkin | 9 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 |
| Leukemia | 8 |
| Leukemia, Myeloid, Acute | 8 |
| Lymphoma, Large B-Cell, Diffuse | 8 |
| Lymphoma, Mantle-Cell | 8 |
Trials
Showing 1 to 25 of 50. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.